Details

Autor(en) / Beteiligte

• Legro, Richard S
• Brzyski, Robert G
• Diamond, Michael P
• Coutifaris, Christos
• Schlaff, William D
• Casson, Peter
• Christman, Gregory M
• Huang, Hao
• Yan, Qingshang
• Alvero, Ruben
• Haisenleder, Daniel J
• Barnhart, Kurt T
• Bates, G. Wright
• Usadi, Rebecca
• Lucidi, Scott
• Baker, Valerie
• Trussell, J.C
• Krawetz, Stephen A
• Snyder, Peter
• Ohl, Dana
• Santoro, Nanette
• Eisenberg, Esther
• Zhang, Heping

Titel

Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome

Ist Teil von

• The New England journal of medicine, 2014-07, Vol.371 (2), p.119-129

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• This double-blind, multicenter, randomized trial showed that letrozole, as compared with clomiphene, was associated with higher live-birth and ovulation rates among infertile women with the polycystic ovary syndrome. The polycystic ovary syndrome, which is diagnosed on the basis of hyperandrogenism, oligo-ovulation with associated oligomenorrhea, and polycystic ovaries on ultrasonography, affects 5 to 10% of reproductive-age women and is the most common cause of anovulatory infertility. 1 Although the syndrome is a complex reproductive–metabolic disorder, the hypothalamic–pituitary axis has been the target of first-line ovulation-induction therapy. Clomiphene citrate, a selective estrogen-receptor modulator that antagonizes the negative feedback of estrogen at the hypothalamus with a consequent increase in ovarian stimulation by endogenous gonadotropin, has been used for this indication for decades. Clomiphene has drawbacks, including its overall poor efficacy (only a . . .